Biomarkers Trials and Combinations in Cervical Cancer

Clinical management in recurrent cervical cancer increasingly depends on both practical toxicity prevention and thoughtful biomarker assessment. The faculty describe specific supportive care measures used to reduce ocular complications with tisotumab vedotin, including topical vasoconstricting drops and cooling strategies around treatment administration. Biomarker testing is discussed in parallel, with clarification that tissue factor targeting does not require routine selection testing for tisotumab vedotin, whereas HER2 testing remains relevant for the smaller subset of patients who may be candidates for trastuzumab deruxtecan. Programmed death ligand 1 evaluation and broader molecular profiling also remain important when recurrent disease prompts a search for additional treatment options. Beyond currently available agents, the conversation surveys ongoing clinical trials involving TROPE2 directed therapy and other investigational antibody drug conjugates that may further expand the field. Interest is especially strong in combination strategies with immunotherapy, where more effective integration of targeted therapy and checkpoint inhibition could eventually change the way recurrent cervical cancer is treated.